Trial Profile
Multicenter trial using multi-dose rituximab as induction and desensitization therapy for patients on the waiting list for kidney transplant with a positive donor specific crossmatch to a living donor
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 25 Oct 2023
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 20 Oct 2023 According to ClinicalTrials.gov record NCT00476515, this study has been withdrawn as protocol to be revised.
- 20 Oct 2023 According to ClinicalTrials.gov record NCT00476515, this study has been withdrawn as protocol to be revised.
- 20 Oct 2009 Actual end date (Sep 2007) added as reported by ClinicalTrials.gov.